Company intelligence / Profile preview
Black Diamond Therapeutics
Cambridge, Massachusetts, United Statesblackdiamondtherapeutics.com ↗
- Ownership
- Public · BDTX
- Development stage
- Other
01
Overview
BDTX-1535 has demonstrated robust Phase 2 clinical activity across a broad spectrum of epidermal growth factor receptor mutations in NSCLC. The company is advancing BDTX-1535 towards pivotal development with additional Phase 2 data expected in Q1 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Servier
04
Financials
- Market cap
- $95.1M
- Total revenue
- $70M
- Enterprise value
- $1.6M
Beyond the preview
Go deeper on Black Diamond Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Black Diamond Therapeutics.